Please use this identifier to cite or link to this item: https://doi.org/10.1159/000524435
Title: Evaluating the Initiation of Sodium/Glucose Cotransporter 2 Inhibitors within 2 Weeks of an Acute Hospital Admission: A Systematic Review and Meta-Analysis of Nine Clinical Trials
Authors: Chieng, Jenny Hui Ling
Sia, Tze Kai
Teo, Yao Hao
Wong, Joseph Zi An
Ng, Tricia Jing Ying
Teo, Yao Neng
Syn, Nicholas L.X.
Cherian, Robin 
Lim, Yoke-Ching 
Chai, Ping 
Lin, Weiqin 
Wong, Raymond C.C. 
Sia, Ching-Hui 
Keywords: Sodium/glucose cotransporter 2 inhibitors
Acute hospital admission
Efficacy outcomes
Safety outcomes
Issue Date: 4-Apr-2022
Publisher: S. Karger AG
Citation: Chieng, Jenny Hui Ling, Sia, Tze Kai, Teo, Yao Hao, Wong, Joseph Zi An, Ng, Tricia Jing Ying, Teo, Yao Neng, Syn, Nicholas L.X., Cherian, Robin, Lim, Yoke-Ching, Chai, Ping, Lin, Weiqin, Wong, Raymond C.C., Sia, Ching-Hui (2022-04-04). Evaluating the Initiation of Sodium/Glucose Cotransporter 2 Inhibitors within 2 Weeks of an Acute Hospital Admission: A Systematic Review and Meta-Analysis of Nine Clinical Trials. Medical Principles and Practice 31 (3) : 215-223. ScholarBank@NUS Repository. https://doi.org/10.1159/000524435
Rights: Attribution-NonCommercial 4.0 International
Abstract: Objective: Recent studies have increasingly shown the benefits of using sodium/glucose cotransporter 2 inhibitor (SGLT2i). However, there are concerns regarding the initiation of SGLT2i during acute hospital admissions due to the potential increased risk of complications. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of SGLT2i initiation within 2 weeks of an acute hospital admission. Methods: Four electronic databases (PubMed, Embase, Cochrane, and Scopus) were searched for articles published from inception up to 27 March 2021 that evaluated the efficacy and/or safety of SGLT2i initiation within 2 weeks of an acute hospital admission. Random-effects pair-wise meta-analysis models were utilized to summarize the studies. The protocol was registered with PROSPERO (CRD42021245492). Results: Nine clinical trials were included with a combined cohort of 1,758 patients. Patients receiving SGLT2i had a mean increase in 24-h urine volume of +487.55 mL (95% CI 126.86–848.25; p = 0.008) compared to those not started on SGLT2i. Patients with heart failure treated with SGLT2i had a 27% relative risk reduction in rehospitalizations for heart failure, compared to controls (risk ratio 0.73; p = 0.005). There were no differences in other efficacy and safety outcomes examined. Conclusion: There was no increased harm with initiation of SGLT2i within 2 weeks of an acute hospital admission, and its use reduced the relative risk of rehospitalizations for heart failure in patients with heart failure. It was also associated with increased urine output. However, current evidence pool is limited, especially in specific population subtypes.
Source Title: Medical Principles and Practice
URI: https://scholarbank.nus.edu.sg/handle/10635/228734
ISSN: 1011-7571
1423-0151
DOI: 10.1159/000524435
Rights: Attribution-NonCommercial 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
MPP524435.pdf360.79 kBAdobe PDF

OPEN

NoneView/Download

Page view(s)

40
checked on Nov 17, 2022

Download(s)

16
checked on Nov 17, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons